For pharmaceutical companies planning global launches, understanding drug approval timelines across regions is critical.

While Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is aligned with global standards through ICH, approval timelines in Japan can differ significantly from those of the FDA (US) and EMA (EU).

How Do PMDA Timelines Compare?

In general:

• FDA is often considered the fastest for innovative therapies
• EMA follows a centralized review structure across Europe
• PMDA combines detailed scientific review with consultation-driven evaluation

Japan approvals can be highly efficient—but timelines often depend on:

• Early PMDA consultation strategy
• Availability of Japan-relevant clinical data
• Bridging study requirements
• CMC localization and dossier quality

Why Do Delays Happen in Japan?

Many global submissions experience delays because:

• Japan is included late in global development plans
• Global data does not fully align with PMDA expectations
• Module 3 (CMC) lacks localization
• Additional clarification or consultation rounds are required

In many cases, delays are strategic—not scientific.

What Helps Accelerate PMDA Review?

Companies that succeed in Japan typically:

• Engage PMDA early during development
• Align clinical and CMC strategy with local expectations
• Prepare Japan-ready CTD/eCTD dossiers
• Build structured lifecycle and post-marketing plans

PMDA timelines are not necessarily slower than FDA or EMA—but they are more dependent on preparation, localization, and early regulatory alignment. 

For companies entering Japan, success is often determined long before submission begins. Connect with our experts